HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PFE
Pfizer Inc.
PFE's fundamentals are mixed, but it looks expensive: trading at 41x earnings, more than twice its usual 15x. Its downside scenario is about four times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PFE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
PFE's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PFE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $6.78 | -76% |
| Forward | 10x | $28.83 | — |
| Fair | 15x | $10.59 | -63% |
| Expensive | 24x | $16.53 | -43% |
| Current | 41x | $28.83 | — |
Historical ranges are pointers, not guarantees.
PFE's PE is in its expensive range at 41x. On analysts' estimates for next year's earnings, today's price would be 10x, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PFE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect PFE's profitability to improve, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PFE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.83 | +304% |
| Q3 2026 | $0.70 | -59% |
| Q2 2026 | $0.76 | -60% |
| Q1 2026 | $1.31 | -5.1% |
| Q4 2025 | $1.36 | -3.5% |
| Q3 2025 | $1.72 | +129% |
| Q2 2025 | $1.88 | +$2.33 |
| Q1 2025 | $1.38 | +$1.43 |
| Q4 2024 | $1.41 | +281% |
PFE has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PFE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PFE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.6B | -0.4% |
| Q2 2026 | $15B | +2.6% |
| Q1 2026 | $14.5B | +5.4% |
| Q4 2025 | $17.6B | -1.2% |
| Q3 2025 | $16.7B | -5.9% |
| Q2 2025 | $14.7B | +10% |
| Q1 2025 | $13.7B | -7.8% |
| Q4 2024 | $17.8B | +25% |
PFE's revenue fell from its 2022 peak and has held roughly level since: $16.6B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +0.4 points |
| Q2 2026 | -4.3% | -25 points |
| Q1 2026 | 22% | +1.6 points |
| Q4 2025 | -9.3% | -9.3 points |
| Q3 2025 | 20% | -6.6 points |
| Q2 2025 | 21% | +22 points |
| Q1 2025 | 20% | -2.7 points |
| Q4 2024 | -0.1% | +29 points |
PFE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PFE on cash flow, with more consistent year-over-year improvement.
PFE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +20% |
| Q2 2026 | $302M | +$1.5B |
| Q1 2026 | $2.2B | +23% |
| Q4 2025 | $4.5B | -22% |
| Q3 2025 | $4B | -34% |
| Q2 2025 | -$1.2B | +$1.2B |
| Q1 2025 | $1.8B | +359% |
| Q4 2024 | $5.8B | +38% |
PFE still generates free cash flow, though less than at its 2021 peak: $11.8B over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PFE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PFE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +52M shares |
| 1 year | +0.6% | +37M shares |
| 3 years | +1.9% | +105M shares |
| 5 years | +0.5% | +26M shares |
| Available history | -3.9% | -230M shares |
PFE has 5.8B diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | $2B |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PFE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.7x | High |
| Q2 2026 | 5.8x | High |
| Q1 2026 | 4.3x | High |
| Q4 2025 | 4.5x | High |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 4.3x | High |
| Q4 2024 | 4.2x | High |
PFE's net debt is about 5.7 years of its operating earnings (EBITDA), up from 3.8 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PFE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.8 | Neutral |
| Stochastic | 72.5 | Neutral |
PFE's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PFE PE vs Healthcare Sector
| Metric | PFE | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 59% above |
| PE % | 97 | 29 | 68 pts above |
PFE is trading at 41x earnings, a 59% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PFE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 1.1% below |
| 20 week MA | $27.5 | 4.9% above |
| 50 week MA | $26.8 | 7.7% above |
| 100 week MA | $25.8 | 12% above |
| 200 week MA | $29.0 | 0.4% below |
PFE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PFE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.3 | $37.3 | 0% |
| 2021 | $37.3 | $58.7 | +58% |
| 2022 | $58.7 | $51.8 | -12% |
| 2023 | $51.8 | $28.8 | -44% |
| 2024 | $28.8 | $26.6 | -7.5% |
| 2025 | $26.6 | $25.1 | -5.7% |
| 2026 YTD | $25.1 | $28.8 | +15% |
PFE has the edge over HIMS on returns for 2026, with the stronger performance.